REDWOOD CITY, November 17, 2026 — The European Commission has approved RASONQUE (daraxonrasib), the first broad RAS-targeted medicine for metastatic pancreatic cancer, offering new hope to patients who have long faced limited treatment options.
A Long History of Limited Options
For decades, physicians treating metastatic pancreatic cancer have had limited options beyond cytotoxic chemotherapy. The disease is notoriously aggressive and difficult to treat. Pancreatic adenocarcinoma, the most common type, accounts for about 90% of pancreatic cancer cases. Symptoms typically do not develop until the disease has reached an advanced stage, and by the time of diagnosis, the cancer has often spread to other parts of the body. This contributes to a grim prognosis: less than a quarter of people with pancreatic cancer are still alive a year after diagnosis.
How Daraxonrasib Works
RASONQUE is given once daily as oral tablets and is approved for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy. A key aspect of this approval is that it is for patients with or without an identified RAS tumor mutation. This is significant because many previous treatments were only effective for patients with a specific genetic mutation. Daraxonrasib represents a broad RAS-targeted medicine, designed to work against a wider range of these cancers.
Clinical Trial Results
The approval is based on results from the Phase 3 RASolute 302 clinical trial, which was presented at the 2026 American Society of Clinical Oncology Annual Meeting and published in The New England Journal of Medicine. The trial demonstrated unprecedented survival benefits with daraxonrasib compared to the previous standard of care. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) also supported the approval, noting its potential to address a high unmet medical need as part of an expedited review.
A New Standard of Care in the EU
“Today’s European Commission approval of RASONQUE represents a pivotal moment for people in the European Union living with metastatic pancreatic cancer, as well as their families,” said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. The company is now working with healthcare systems across the region to support timely access for eligible patients. Dr. Thomas Seufferlein, medical director at Ulm University Hospital, called the approval an “important advance” and noted that the survival benefit demonstrated in the trial has the potential to establish a new standard of care. This new standard offers a concrete improvement in outcomes for a patient population that has seen little progress for many years. For patients and their families, this means a new possibility for more time.
Sources
- European Commission Approves Revolution Medicines’ RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
- Pancreatic cancer
- Experimental Vaccine for Pancreatic Cancer Could Help Find and Destroy Lurking Cancer Cells
- I was 28 and running marathons – bombshell diagnosis gave me 18 months to live
- Verastem Weighs Partnership or Solo Launch as Cancer Drug Trials Advance
- Immune Driver of Pancreatic Cancer Points to Combination Treatment
Photo: Gold Standard Analytics LLC (CC BY-SA 4.0)





